Ai Ning, Li Bo, Li Li, Li Zhigang, Ji Hong, Yang Guang, Yin Fenghua
Department of Interventional Radiology, The Fourth Hospital of Hebei Medical University, Shijiangzhuang, Hebei 050011, P.R. China.
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiangzhuang, Hebei 050011, P.R. China.
Exp Ther Med. 2019 Aug;18(2):1493-1499. doi: 10.3892/etm.2019.7709. Epub 2019 Jun 25.
MicroRNA-466 was recently characterized as a tumor suppressor with known biological function in prostate cancer. The aim of the current study was to investigate the possible involvement of microRNA-466 in hepatocellular carcinoma (HCC). The current study demonstrated that the expression level of microRNA-466 was significantly downregulated; while the mRNA expression level of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) was significantly upregulated in tumor tissue compared with adjacent healthy tissue samples obtained from patients with HCC. In addition, the relative plasma level of microRNA-466 was significantly decreased, while the relative plasma level of ROCK2 was significantly increased in patients with HCC compared with healthy controls. Expression levels of microRNA-466 and ROCK2 were inversely correlated in tumor tissue but not in adjacent healthy tissue samples obtained from patients with HCC. Plasma levels of microRNA-466 and ROCK2 were inversely correlated in patients with HCC but not in healthy controls. In addition, reduced plasma levels of microRNA-466 may have a diagnostic value in the detection of early stage HCC. MicroRNA-466 overexpression significantly suppressed ROCK2 expression in HCC cells, whereas ROCK2 overexpression did not significantly affect microRNA-466 expression. MicroRNA-466 overexpression significantly suppressed, while ROCK2 overexpression significantly enhanced HCC cell migration and invasion. In addition, ROCK2 overexpression partially reversed the inhibitory effect of microRNA-466 overexpression on HCC cell migration and invasion. Taken together, these results suggest that microRNA-466 may inhibit HCC cell migration and invasion by indirectly mediating the downregulation of ROCK2.
微小RNA - 466最近被鉴定为一种在前列腺癌中具有已知生物学功能的肿瘤抑制因子。本研究的目的是探讨微小RNA - 466在肝细胞癌（HCC）中的可能作用。本研究表明，与从HCC患者获得的相邻健康组织样本相比，肿瘤组织中微小RNA - 466的表达水平显著下调；而含Rho相关卷曲螺旋蛋白激酶2（ROCK2）的mRNA表达水平显著上调。此外，与健康对照相比，HCC患者血浆中微小RNA - 466的相对水平显著降低，而ROCK2的相对血浆水平显著升高。在肿瘤组织中，微小RNA - 466和ROCK2的表达水平呈负相关，但在从HCC患者获得的相邻健康组织样本中并非如此。在HCC患者中，微小RNA - 466和ROCK2的血浆水平呈负相关，但在健康对照中并非如此。此外，血浆中微小RNA - 466水平降低可能对早期HCC的检测具有诊断价值。微小RNA - 466过表达显著抑制HCC细胞中ROCK2的表达，而ROCK2过表达对微小RNA - 466的表达没有显著影响。微小RNA - 466过表达显著抑制，而ROCK2过表达显著增强HCC细胞的迁移和侵袭。此外，ROCK2过表达部分逆转了微小RNA - 466过表达对HCC细胞迁移和侵袭的抑制作用。综上所述，这些结果表明微小RNA - 466可能通过间接介导ROCK2的下调来抑制HCC细胞的迁移和侵袭。
